1057 related articles for article (PubMed ID: 33970288)
1. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.
Chari A; Richardson PG; Romanus D; Dimopoulos MA; Sonneveld P; Terpos E; Hajek R; Raju A; Palumbo A; Cain LE; Blazer M; Huang H; Farrelly E; Ailawadhi S
Expert Rev Hematol; 2020 Apr; 13(4):421-433. PubMed ID: 32148109
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L
Curr Probl Cancer; 2024 Mar; 50():101078. PubMed ID: 38547609
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
5. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
6. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
7. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
8. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
10. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
13. A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting.
Rifkin RM; Medhekar R; Amirian ES; Aguilar KM; Wilson T; Boyd M; Mezzi K; Panjabi S
Ther Adv Hematol; 2019; 10():2040620718816699. PubMed ID: 30719266
[TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
DerSarkissian M; Cranmer H; Dabora J; Bocharova I; Cherepanov D; Cheng M; Bhak RH; Duh MS
Hematology; 2023 Dec; 28(1):2156731. PubMed ID: 36607147
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
[No Abstract] [Full Text] [Related]
19. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
